Increasing rates of ciprofloxacin resistant campylobacter

Sam, W I C; Lyons, Michael M.; Waghorn, David

doi:10.1136/jcp.52.9.709

Cited by 17 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of poultry consumption in the antimicrobial resistance of clinical Campylobacter strains is further supported by different observational studies in other European countries, such as the Netherlands and Spain, and in the United States and Canada that linked the rise of fluoroquinolone-resistant C. jejuni infections in humans with the introduction of fluoroquinolones in poultry therapy [23,58]. A similar observation was noted in the with the emergence of fluoroquinolone-resistant Campylobacter following the approval of fluoroquinolones as growth promoters in veterinary practices [59]. These observational studies were corroborated by an experimental study that demonstrated the emergence of ciprofloxacin-resistant C. jejuni strains in broiler flocks following enrofloxacin therapy [60].…”

Section: Discussionmentioning

confidence: 60%

Antimicrobial resistance patterns and molecular resistance markers of Campylobacter jejuni isolates from human diarrheal cases

et al. 2020

View full text Add to dashboard Cite

The aim of this study is to characterize the antimicrobial resistance of Campylobacter jejuni recovered from diarrheal patients in Belgium, focusing on the genetic diversity of resistant strains and underlying molecular mechanisms of resistance among Campylobacter jejuni resistant strains isolated from diarrheal patients in Belgium. Susceptibility profile of 199 clinical C. jejuni isolates was determined by minimum inhibitory concentrations against six commonly-used antibiotics (ciprofloxacin, nalidixic acid, tetracycline, streptomycin, gentamicin, and erythromycin). High rates of resistance were observed against nalidixic acid (56.3%), ciprofloxacin (55.8%) and tetracycline (49.7%); these rates were similar to those obtained from different national reports in broilers intended for human consumption. Alternatively, lower resistance rates to streptomycin (4.5%) and erythromycin (2%), and absolute sensitivity to gentamicin were observed. C. jejuni isolates resistant to tetracycline or quinolones (ciprofloxacin and/or nalidixic acid) were screened for the presence of the tetO gene and the C257T mutation in the quinolone resistance determining region (QRDR) of the gyrase gene gyrA, respectively. Interestingly, some of the isolates that displayed phenotypic resistance to these antimicrobials lacked the corresponding genetic determinants. Among erythromycin-resistant isolates, a diverse array of potential molecular resistance mechanisms was investigated, including the presence of ermB and mutations in the 23S rRNA gene, the rplD and rplV ribosomal genes, and the regulatory region of the cmeABC operon. Two of the four erythromycin-resistant isolates harboured the A2075G transition mutation in the 23S rRNA gene; one of these isolates exhibited further mutations in rplD, rplV and in the cmeABC regulatory region. This study expands the current understanding of how different genetic PLOS ONE | https://doi.

show abstract

Section: Discussionmentioning

confidence: 60%

Antimicrobial resistance patterns and molecular resistance markers of Campylobacter jejuni isolates from human diarrheal cases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the early 1990s, when enrofloxacin was introduced into animal production in Asia and in Europe, at the same time fluoroquinolone resistance started to increase among human Campylobacter isolates [32]. The same phenomenon was observed in UK and USA after the approval of the use of fluoroquinolones in veterinary medicine [13, 82]. In many countries, where fluoroquinolone use in animal production is low, the incidence of fluoroquinolone-resistant strains has remained moderate or low.…”

Section: Factors Influencing Antimicrobial Resistance Of Campylobamentioning

confidence: 96%

“…In Europe, the emergence of fluoroquinolone resistance evaluated between 1993 and 2003 in Spain showed a statistically significant increase for nalidixic acid (46.7% of the isolates) and ciprofloxacin (52.2%) [93]. Similarly, in the United Kingdom, resistance to fluoroquinolones in Campylobacter isolates was observed after the approval of the use of the antimicrobials as growth promoters in food producing animals [82]. An increasing resistance to fluoroquinolones among Campylobacter strains isolated from poultry was also observed in Poland where during 1994–1996 and 2005–2008 47.9% and 90.2% of such isolates were resistant to ciprofloxacin, respectively [94].…”

Section: Epidemiology Of Fluoroquinolone and Macrolide Resistance mentioning

confidence: 99%

Antimicrobial Resistance Mechanisms amongCampylobacter

Wieczorek

Osek

2013

BioMed Research International

247

269

View full text Add to dashboard Cite

Campylobacter jejuni and Campylobacter coli are recognized as the most common causative agents of bacterial gastroenteritis in the world. Humans most often become infected by ingesting contaminated food, especially undercooked chicken, but also other sources of bacteria have been described. Campylobacteriosis is normally a self-limiting disease. Antimicrobial treatment is needed only in patients with more severe disease and in those who are immunologically compromised. The most common antimicrobial agents used in the treatment of Campylobacter infections are macrolides, such as erythromycin, and fluoroquinolones, such as ciprofloxacin. Tetracyclines have been suggested as an alternative choice in the treatment of clinical campylobacteriosis but in practice are not often used. However, during the past few decades an increasing number of resistant Campylobacter isolates have developed resistance to fluoroquinolones and other antimicrobials such as macrolides, aminoglycosides, and beta-lactams. Trends in antimicrobial resistance have shown a clear correlation between use of antibiotics in the veterinary medicine and animal production and resistant isolates of Campylobacter in humans. In this review, the patterns of emerging resistance to the antimicrobial agents useful in treatment of the disease are presented and the mechanisms of resistance to these drugs in Campylobacter are discussed.

show abstract

“…The initiation of the administration of the fluoroquinolone, enrofloxacin, to food animals began in the early 1990s in Asia and in European countries such as Sweden, the Netherlands and Spain coincided with primary resistance to fluoroquinolone therapy in humans in those countries (Endtz et al , 1991). Similarly, in the United Kingdom, resistance to fluoroquinolones in Campylobacter isolates was observed after the approval of the use of the fluoroquinolones as growth promoters in veterinary animals (Sam et al , 1999). In the United States, the introduction of sarafloxacin and enrofloxacin in the mid‐1990s for use as growth promoters in poultry flocks also contributed to fluoroquinolone resistance, with resistance among Campylobacter isolates from humans increasing from 1.3% in 1992 to 10.2% in 1998 (Nachamkin et al , 2002).…”

Section: Introductionmentioning

confidence: 99%

Antibiotic resistance and resistance mechanisms inCampylobacter jejuniandCampylobacter coli

Alfredson

Korolik

2007

FEMS Microbiology Letters

197

133

View full text Add to dashboard Cite

Campylobacter jejuni and Campylobacter coli are recognized as the most common causative agents of bacterial gastroenteritis in the world and infections with these organisms occur more frequently than do infections due to Salmonella species, Shigella species, or Escherichia coli 0157:H7. The incidence of human Campylobacter infections has increased markedly in both developed and developing countries worldwide and, more significantly, so has the rapid emergence of antibiotic-resistant Campylobacter strains, with evidence suggesting that the use of antibiotics, in particular the fluoroquinolones, as growth promoters in food animals and the veterinary industry is accelerating this trend. In this minireview, the patterns of emerging resistance to the antimicrobial agents useful in treatment of the disease are presented and the mechanisms of resistance to these drugs in Campylobacter spp are discussed.

show abstract

Increasing rates of ciprofloxacin resistant campylobacter

Cited by 17 publications

References 7 publications

Antimicrobial resistance patterns and molecular resistance markers of Campylobacter jejuni isolates from human diarrheal cases

Antimicrobial resistance patterns and molecular resistance markers of Campylobacter jejuni isolates from human diarrheal cases

Antimicrobial Resistance Mechanisms amongCampylobacter

Antibiotic resistance and resistance mechanisms inCampylobacter jejuniandCampylobacter coli

Contact Info

Product

Resources

About